Galmed Pharmaceuticals (GLMD)

Galmed Pharmaceuticals (GLMD) Financial Statements


Galmed Pharmaceuticals Financial Overview

Galmed Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-1.817; its P/E ratio is -0.17; Galmed Pharmaceuticals is scheduled to report earnings on May 7, 2025, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue-$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit-----
EBIT-$ -5.38M$ -3.73M$ -6.09M$ -7.49M
EBITDA-$ -5.37M$ -3.72M$ -6.08M$ -7.48M
Net Income Common Stockholders-$ -5.35M$ -3.73M$ -6.14M$ -7.45M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 13.90M$ 19.21M$ 22.40M$ 28.74M$ 34.81M
Total Assets$ 16.56M$ 20.87M$ 23.57M$ 30.20M$ 36.60M
Total Debt$ 578.00K$ 89.00K$ 134.00K$ 183.00K$ 229.00K
Net Debt$ -13.32M$ -19.12M$ -22.27M$ -28.56M$ -34.59M
Total Liabilities$ 3.14M$ 5.12M$ 2.86M$ 5.83M$ 6.11M
Stockholders Equity$ 13.42M$ 15.75M$ 20.71M$ 24.37M$ 30.50M
Cash Flow-
Free Cash Flow-$ -3.11M$ -5.91M$ -5.45M$ -6.99M
Operating Cash Flow-$ -3.11M$ -5.91M$ -5.45M$ -6.99M
Investing Cash Flow-$ 5.13M$ 4.15M$ 6.31M$ 6.38M
Financing Cash Flow-$ 70.00K$ 0.00$ 0.00$ 0.00
Currency in USD

Galmed Pharmaceuticals Earnings and Revenue History

Galmed Pharmaceuticals Debt to Assets

Galmed Pharmaceuticals Cash Flow

Galmed Pharmaceuticals Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis